Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PDD -17.1%, SKY -8.6%, BNS -1.1%
Other news:
- RCKT -62.8% (provides update on phase 2 clinical trial of RP-A501 for Danon Disease)
- PRTA -28.6% (Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint)
- HMY -9.5% (MAC Limited enters binding scheme implementation deed with Harmony Gold Mining (HMY))
- YMAB -4.9% (Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting)
- PBT -2.9% (files second amended petition against Blackbeard Operating)
- TMQ -2.4% (enters into at-the-market equity distribution agreement)
- EYPT -2.3% (completes enrollment in pivotal phase 3 LUGANO Trial of DURAVYU for treatment of wet age-related macular degeneration)
- FNV -2.2% (acquires royalty package on the Côté Gold Mine)
- CDE -1.7% (authorized a $75 million share repurchase program, effective through May 31, 2026)
- FSM -1.5% (drills 8.6 g/t gold over 13.6 meters at Southern Arc prospect)
- ONC -1.4% (announced that the CHMP of the EMA issued a positive opinion recommending approval of TEVIMBRA (tislelizumab), in combination with gemcitabine and cisplatin)
- TCOM -1% (repurchases right notification for 1.50% exchangeable senior notes due 2027)
- DASH -1% (announces proposed private offering of $2.0 billion of convertible senior notes)